Dual Rapid HIV & Syphilis Tests in Zambia

计划入组 3,010 人 · 首次发布于 2015 年 5 月 15 日

Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)

计划入组 60 人 · 首次发布于 2016 年 6 月 16 日

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

计划入组 285 人 · 首次发布于 2019 年 6 月 28 日

ISH-0613

ISH-0339

ISH-0869

Zymeworks

Canada

Sona Nanotech Inc

Canada

Nuvalent

United States

Roche Advances in TIGIT Immunotherapy and AI-Driven Biomarker Development Signal Strategic Shift in Precision Oncology

FDA Clears Roche's VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail for B-Cell Lymphoma Diagnosis

Roche Receives FDA and CE-IVDR Approvals for Expanded HER2 Diagnostic Applications in Cancer Treatment